Seattle Reproductive Medicine, 1505 Westlake Avenue, Suite 400, Seattle, WA, 98104, USA.
J Assist Reprod Genet. 2021 Jul;38(7):1617-1625. doi: 10.1007/s10815-021-02159-4. Epub 2021 Apr 19.
Decision-making in fertility care is on the cusp of a significant frameshift. Online tools to integrate artificial intelligence into the decision-making process across all aspects of ART are rapidly emerging. These tools have the potential to improve outcomes and transition decision-making from one based on traditional provider centric assessments toward a hybrid triad of expertise, evidence, and algorithmic data analytics using AI. We can look forward to a time when AI will be the third part of a provider's tool box to complement expertise and medical literature to enable ever more accurate predictions and outcomes in ART. In their fully integrated format, these tools will be part of a digital fertility ecosystem of analytics embedded within an EMR. To date, the impact of AI on ART outcomes is inconclusive. No prospective studies have shown clear cut benefit or cost reductions over current practices, but we are very early in the process of developing and evaluating these tools. We owe it to ourselves to begin to examine these AI-driven analytics and develop a very clear idea about where we can and should go before we roll these tools into clinical care. Thoughtful scrutiny is essential lest we find ourselves in a position of trying to modulate and modify after entry of these tools into our clinics and patient care. The purpose of this commentary is to highlight the evolution and impact AI has had in other fields relevant to the fertility sector and describe a vision for applications within ART that could improve outcomes, reduce costs, and positively impact clinical care.
生育护理中的决策正处于重大转变的边缘。将人工智能集成到 ART 各个方面决策过程中的在线工具正在迅速涌现。这些工具有可能改善结果,并将决策从基于传统提供者为中心的评估转变为专家、证据和使用 AI 的算法数据分析的混合三位一体。我们可以期待有一天,人工智能将成为提供者工具包的第三部分,以补充专业知识和医学文献,从而在 ART 中实现更准确的预测和结果。在其完全集成的形式下,这些工具将成为嵌入电子病历 (EMR) 的数字生育生态系统分析的一部分。到目前为止,人工智能对 ART 结果的影响尚无定论。没有前瞻性研究表明在当前实践基础上有明显的获益或成本降低,但我们还处于开发和评估这些工具的早期阶段。在将这些工具引入临床护理之前,我们有责任开始研究这些人工智能驱动的分析,并清楚地了解我们可以并且应该在哪些方面进行。审慎的审查至关重要,以免我们发现自己处于这些工具进入我们的诊所和患者护理后试图调节和修改的境地。本评论的目的是强调人工智能在与生育领域相关的其他领域中的发展和影响,并描述在 ART 中应用的愿景,这些应用有可能改善结果、降低成本并对临床护理产生积极影响。